Cancer Control最新文献

{"title":"The Role of GPX1 (rs1050450) Variants in Ovarian Cancer Susceptibility Within a Turkish Population.","authors":"Baker Alsheikh, Rukset Attar, Seda Güleç Yilmaz, Sara Yaser Barham, Selvi Duman Bakırezer","doi":"10.1177/10732748251332441","DOIUrl":"https://doi.org/10.1177/10732748251332441","url":null,"abstract":"<p><p>IntroductionOvarian cancer (OC) remains one of the most lethal gynecological malignancies, primarily due to challenges in early detection and the consequent poor prognosis. Genetic predisposition plays a critical role in OC development, with the Glutathione Peroxidase 1 (GPX1) gene receiving increasing attention. The GPX1 gene polymorphism rs1050450 has been implicated in various cancers, potentially through its impact on oxidative stress mechanisms.ObjectiveThis study aimed to investigate the association between the GPX1 (rs1050450) polymorphism and the risk of developing OC in a Turkish population.MethodsA retrospective case-control study was conducted involving 90 women diagnosed with OC and 90 healthy controls. Genotyping of the GPX1 (rs1050450) polymorphism was performed using real-time PCR (RT-PCR). Statistical analyses were conducted using the SPSS software, with chi-square and t-tests applied where appropriate.ResultsThe CC genotype of the GPX1 (rs1050450) polymorphism was significantly associated with a reduced risk of OC (<i>P</i> = 0.002; OR = 0.304; 95% CI = 0.161-0.577), whereas the TT genotype was linked to an increased risk, demonstrating a threefold elevation in susceptibility (<i>P</i> = 0.036; OR = 3.308; 95% CI = 1.024-10.682). Additionally, the T allele was associated with an approximately threefold increased risk of developing OC (<i>P</i> = 0.0002).ConclusionThese findings suggest that the GPX1 (rs1050450) polymorphism may play a significant role in OC susceptibility, with the CC genotype offering potential protective effects and the TT genotype indicating increased risk. This genetic variant may serve as a useful marker for assessing OC risk; however, further studies involving larger and more diverse populations are needed to validate these results.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251332441"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Difference in the Trend and Forecast Analysis of Changes in the Burden of Disease of Pancreatic Cancer Attributable to Smoking in China, 1990-2021.","authors":"Haodi Wang, Wenhao Sun, Jiaqian Zuo, Gang Wang, Zhengming Deng, Zhiwei Jiang","doi":"10.1177/10732748251341521","DOIUrl":"https://doi.org/10.1177/10732748251341521","url":null,"abstract":"<p><p>BackgroundPancreatic cancer is one of the most aggressive malignant tumors worldwide, often resulting in poor prognosis. Smoking is widely recognized as a significant risk factor for this disease.MethodsThis study extracted data on the disease burden of pancreatic cancer attributable to smoking in China from the Global Burden of Disease 2021 (GBD 2021) database. A total of 447 334 individuals were included in the analysis. A joinpoint regression model was used to calculate the annual percentage change (APC) and average annual percentage change (AAPC) to assess trends in the disease burden from 1990 to 2021. The age-period-cohort model was applied to explain the epidemiological trends of the disease by controlling for variables associated with age, period, and birth cohort. Decomposition analysis was conducted to quantify the relative contributions of population growth, population aging, and epidemiological changes. The Autoregressive Integrated Moving Average (ARIMA) model was utilized to forecast the burden of pancreatic cancer due to smoking in China over the next 15 years.ResultsFrom 1990 to 2021, the age-standardized mortality rate (ASMR) and the age-standardized disability-adjusted life years rate (ASDR) due to smoking-related pancreatic cancer in China exhibited an upward trend. By 2021, the total number of deaths and disability-adjusted life years (DALYs) had almost doubled compared to 1990. The mortality and DALY rates increased with age, peaking at approximately 85 years and 70 years, respectively, indicating a substantial burden on the elderly population. Furthermore, we predict that female ASMR and ASDR may start to decline in the next 15 years; however, the absolute burden remains unchanged. Conversely, the ASMR and ASDR for males continue to rise, indicating an increasing burden, with the male burden consistently surpassing that of females.ConclusionsThis study demonstrates that from 1990 to 2021, the burden of pancreatic cancer attributable to smoking in China has intensified, with significant disparities related to sex and age. The future outlook appears quite severe, given the large population base and accelerating population aging. Strong smoking cessation and control measures specifically targeting elderly males are imperative to limit tobacco exposure among high-risk groups, as these measures are crucial for alleviating the burden of pancreatic cancer in China.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251341521"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Risk Factors for Cause-specific Mortality in Advanced Papillary Thyroid Cancer and Construction of a Competing Risk Model: A SEER-Based Study.","authors":"Yunyi Yang, Xiaoli He, Xiaoxiao Qu, Shufa Tan, Xinyi Fu, Jiawen You, Weijin Huang, Jiayuan Cai, Yanming He, Hongjie Yang","doi":"10.1177/10732748251336412","DOIUrl":"https://doi.org/10.1177/10732748251336412","url":null,"abstract":"<p><p>IntroductionPapillary thyroid carcinoma (PTC) generally has a favorable prognosis, yet advanced PTC has higher recurrence and mortality risks. This study constructs and validates a competing risk model for cause-specific mortality (CSM) in advanced PTC.MethodsStage III-IV PTC cases (AJCC 7th edition) from the SEER database (2010-2015) were analyzed. Patients were split into training and validation sets (7:3). Univariate and multivariate analyses identified independent CSM predictors, forming the basis of a risk prediction nomogram. Model accuracy was evaluated via the C-index and calibration curve.ResultsA total of 11 913 advanced PTC cases were analyzed. Competing risk model analysis unraveled that age, race, sex, grade, stage, T stage, M stage, surgery, chemotherapy, and tumor size were risk factors for CSM in advanced PTC. The AUC values of the constructed nomogram in predicting 3-, 5-, and 8-year survival were 0.931 (95%CI 0.909-0.953), 0.915 (95%CI 0.897-0.933), and 0.902 (95%CI 0.883-0.92) in the training set, and 0.948 (95%CI 0.916-0.981), 0.93 (95 % CI 0.903-0.957), and 0.917 (95%CI 0.891-0.943) in the validation cohort, respectively. The C-index of the nomogram for advanced PTC was 0.908 and 0.921 in the training and validation cohorts, respectively. The calibration curve unveiled that the predicted estimates by the model were basically congruent with the observed values, suggesting a high degree of calibration.ConclusionThe competing risk model offers a reliable tool for assessing prognosis in advanced PTC, supporting personalized treatment and risk management in clinical practice.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336412"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.","authors":"Donghong Wang, Zhibin Ma","doi":"10.1177/10732748251330713","DOIUrl":"10.1177/10732748251330713","url":null,"abstract":"<p><p>BackgroundPancreatic cancer places a substantial global health and economic burden. However, the epidemiological characteristics and chronological trends of pancreatic cancer in high-income Asia-Pacific have not been systematically analyzed.MethodsData obtained from the GBD 2021 database were used for this cross-country secondary analysis. We used Joinpoint regression to analyze the temporal trends of pancreatic cancer disease burden in the high-income Asia-Pacific. Age-period-cohort model was used to estimate and describe the impact of age, period, and cohort effects on health outcomes. Bayesian age-period-cohort model was used for the projection of pancreatic cancer incidence from 2022 to 2036.ResultsIn high-income Asia-Pacific, the age-standardized prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life-years (DALYs) rate (ASDR) were estimated to be 11.2 (95% UI, 9.69-12.17), 9.56 (95% UI, 8.34-10.34), and 197.6 (95% UI, 178.87-210.6) per 100 000 population, respectively, in 2021, which were all higher than those in across Asia. From 1990 to 2002, the age-standardized incidence rates (ASIRs) trend was rather stable. Instead, the ASIRs trend went up gradually from 2002 to 2011 in both males (APC = + 1.03, 95% CI: 0.85, 1.20) and females (APC = + 1.64, 95% CI: 1.40, 1.89). ASIRs and ASMRs went up considerably with increasing age, especially over 60. The ASIRs in the high-income Asia-Pacific region are predicted to go down in the years ahead, from approximately 12.81 in 2021 to approximately 11.11 in 2036 for males, and from approximately 8.97 in 2021 to approximately 8.42 in 2036 for females.ConclusionA comprehensive upward trend in ASIRs, ASPRs, ASMRs, and ASDRs of pancreatic cancer was observed in the high-income Asia-Pacific between 1990 and 2021. Given the poor prognosis of pancreatic cancer, prevention strategies are paramount, especially for modifiable factors like smoking, alcohol drinking, and obesity.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330713"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing Artificial Intelligence-Powered Virtual Tumor Board Meetings in Pakistan.","authors":"Saqib Raza Khan, Anoud Khan, Aryan Tareen","doi":"10.1177/10732748251331753","DOIUrl":"10.1177/10732748251331753","url":null,"abstract":"<p><p>Equitable cancer care in low- and middle-income countries is crucial as mortality rates continue to rise. Artificial intelligence (AI)-powered Virtual Tumor Board Meetings (VTBMs) offer an innovative solution that facilitates real-time collaboration between experts to improve patient outcomes. By integrating AI-powered tools, VTBMs can improve diagnostic accuracy and personalize treatment plans using various data sources such as medical images and genomic profiles. In Pakistan, with limited healthcare resources and a high economic burden, the introduction of AI-powered VTBMs has the potential to revolutionize cancer care. This strategic approach will not only address the current challenges in Pakistan, but also serve as a model for improving cancer care in various developing countries.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331753"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence OF HPV IN a Peruvian Healthcare Network: A Descriptive Cross-Sectional Study.","authors":"Jhajaira M Araujo, Maria Ramon-Cotrina, Rosa Quispe-Martinez, Mayra Rios-Rios, Maribel Quispe-Gonzaga, Carlos O Saldaña-Reyes, Paula Medina, Melanie Cornejo, Joseph A Pinto, Richard Dyer","doi":"10.1177/10732748251318386","DOIUrl":"10.1177/10732748251318386","url":null,"abstract":"<p><strong>Introduction: </strong>Human papillomavirus (HPV) infection is a common sexually transmitted infection often associated with cancer development. This study aimed to estimate the prevalence of HPV in women receiving care at the AUNA healthcare network in Peru.</p><p><strong>Methods: </strong>We conducted an observational, descriptive, cross-sectional, retrospective study. A de-identified database of HPV-positive women who underwent the BD Onclarity™ HPV Assay between December 2018 and December 2021 at Auna clinics was analyzed. The database contained information regarding age, city, and HPV type. High-risk HPV types were analyzed individually (16, 18, 31, 45, 51, 52) and pooled [P1 (33, 58), P2 (56,59,66), and P3 (35,39,68)]. The study was approved by an independent research ethics committee in Peru.</p><p><strong>Results: </strong>Of 68,714 women included in the study, the HPV prevalence was 14.21% (N = 9765, 95%CI:13.95%-14.47%). The highest prevalence was detected in Piura (16.85%, 95%CI:15.40%-18.38%), where HPV-51, HPV-52, HPV-P1, HPV-P2, and HPV-P3 were most common compared to other Peruvian cities included in the study. In Arequipa, the prevalence was the lowest (13.58%, 95%CI:12.38%-14.85%), but the percentage prevalence of HPV-16 was the highest compared to other cities. The prevalence of multiple HPV infections was 2.88% (N = 1981, 95%CI:2.76%-3.01%), with most of them co-presenting two types of HPV (N = 1522). The most frequent co-occurrences were P2 and P3, P2 and 52, and P2 and 16. Among HPV-positive women, the mean age was 41.31 years (±9.48) and 25.29% were in the 31-35 years group. HPV-P2 was the most frequent in all age groups except in the 65-72 years group, where HPV-P3 was the most common.</p><p><strong>Conclusion: </strong>HPV prevalence was shown to be highest in Piura, with the most prevalent types being HPV-16, HPV-52, and HPV-P2 (HPV-56, -59, -66). HPV infection was found to be more frequent among women in the 31-35 years age group.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318386"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Outcomes of Osimertinib in EGFR - Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital.","authors":"Thi Nhu Hoa Nguyen, Quang Le Van, Phuong Nguyen Thi Bich, Hau Tran Thi, Van Tai Nguyen, The Dao Minh, Lien Nguyen Duc, Duong Phan Thanh, Lam Ngo Le, Chu Nguyen Van, Hoang Nguyen Cong, Duc Nguyen Dinh, Hung Kien Do","doi":"10.1177/10732748251348429","DOIUrl":"10.1177/10732748251348429","url":null,"abstract":"<p><p>IntroductionThis study aimed to evaluate the therapeutic effect of osimertinib and further to compare the results of osimertinib plus brain radiation vs. osimertinib monotherapy in advanced EGFR-mutant non-small cell lung cancer (NSCLC) patients with brain metastases (BMs).MethodsA retrospective study was conducted involving 62 advanced EGFR-mutant NSCLC patients with BMs who were treated with first-line osimertinib at the Vietnam National Cancer Hospital between April 2019 and December 2023. Patients were categorised in two treatment groups: (1) osimertinib alone (33 patients) and (2) osimertinib combined with locoregional therapy, including stereotactic radiosurgery or whole-brain radiotherapy (29 patients). Endpoints included objective response rate (ORR), central nervous system response rate (CNS-ORR), progression-free survival (PFS), overall survival (OS).ResultsThe systemic ORR was 91.9% and the disease-control rate (DCR) was 96.8%. The CNS-ORR was 91.9% and the CNS-DCR was 100%. The median PFS and median OS achieved were 24.5 and 35.2 months, respectively. There was no significant difference in outcomes between patients in either treatment group with respect to CNS-ORR ( <i>P</i> = 1.0), mean best percentage change from baseline in CNS target lesion size (<i>P</i> = .376), median PFS (<i>P</i> = .656), intracranial progression-free survival (iPFS) (<i>P</i> = .706), or OS (<i>P</i> = .734). The occurrence of any-grade adverse events (AEs) did not differ significantly between the two treatment groups (<i>P</i> = .762). However, in the osimertinib plus brain radiation cohort, 3/29 (10.3%) patients experienced radiotherapy-related AEs (2 cases of brain necrosis, 1 case of leukoencephalopathy), which consisted of one case of grade 3 brain radiation necrosis.ConclusionOsimertinib shows favorable real-world outcomes in improving PFS, OS, and CNS-ORR in advanced EGFR-mutant NSCLC Vietnamese patients with BMs, with no clear additional benefit from combining with brain radiotherapy.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251348429"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a Chemotherapy Toxicity Prediction Model in Older Adults With Cancer in Taiwan.","authors":"Chieh-Ying Chang, Yu-Shin Hung, Ming-Chung Kuo, Wen-Chi Chou","doi":"10.1177/10732748251347902","DOIUrl":"10.1177/10732748251347902","url":null,"abstract":"<p><p>IntroductionThe Cancer and Aging Research Group (CARG) model predicts chemotherapy-related toxicities in older patients; however, its applicability has not been validated in Taiwanese patients. This study aims to validate the CARG model in older Taiwanese patients with solid tumors.MethodsPatients (N = 258) aged ≥65 years with solid tumors from a single medical center, slated for first-line chemotherapy, were recruited between 2018 and 2021, with follow-up until December 31, 2022. Patients were categorized into low- (N = 85), medium- (N = 117), and high- (N = 56) risk based on CARG. Validation of CARG involved receiver operating characteristic (ROC) curves. Individual CARG variables were analyzed using univariate analysis for their impact on toxicities and survival.ResultsToxicities of grades ≥3 were 38.8%, 44.4%, and 67.9% (<i>P</i> = .001) in the three ascending risk groups, and there were significant differences in both hematological (<i>P</i> = .002) and non-hematological (<i>P</i> < .001) toxicities. ROC was 0.631 (95% CI: 0.562-0.700), indicating satisfactory discrimination. One-year overall survival rates were 88.7%, 79.7%, and 63.8%, respectively, in ascending-risk groups, with high-risk groups showing decreased survival (<i>P</i> = .002). In the multivariate analysis, decreased hemoglobin, history of falls, and inability to walk one block remained significantly associated with toxicity. For overall survival, the inability to take medications was the only independent predictor.ConclusionThis prognostic study validated the CARG model in a heterogeneous solid tumor cohort in Taiwan. In addition to predicting both hematological and non-hematological toxicities, CARG could offer insights into patient survival among older individuals with cancer.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347902"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cancer Burden on Patients and Their Families in a Resource-Restricted Country: A Cross-Sectional Survey Study From Georgia.","authors":"Tamar Kakhniashvili, Ivane Kiladze, Nino Okribelashvili","doi":"10.1177/10732748251359407","DOIUrl":"10.1177/10732748251359407","url":null,"abstract":"<p><p>IntroductionPatients and their families face financial difficulties during cancer care. This study aims to assess patients' unmet needs and financial challenges during diagnosis and treatment, representing the first research in the Republic of Georgia to address these economic issues.MethodsIn this multicenter, retrospective, observational study, a questionnaire was distributed, and clinical data were collected from 181 patients undergoing active cancer treatment across 7 tertiary hospitals. The primary outcomes of the study were the patient-reported experience of cancer-related financial burden on the family and the frequency of debt taken for cancer diagnosis or treatment.ResultsThe median age was 63, with 55.2% being female. Most patients (135/181, or 74.5%) reported a \"moderate\" or \"heavy\" economic burden from cancer care. During diagnosis and treatment, 129 patients (71.3%) incurred out-of-pocket costs, and 44.2% took out loans for care, with 10 patients (5.6%) doing so multiple times. The most common reason for debt (76/181) was to cover diagnostic procedures. Only 57 patients (31.5%) reported stable employment at the time of the survey, and among the 149 employed/self-employed, 50 (33.5%) experienced work-related issues due to cancer. Younger patients (≤65) had a tendency to take on debt more frequently (49.5%) compared to older (>65) patients (37%), but this difference was not statistically significant (<i>P</i>-value .097).ConclusionCancer care in Georgia imposes a heavy financial burden, with significant out-of-pocket costs for most patients. Improved access to financial assistance is required to better avoid potential inequities.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251359407"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Duloxetine With Mirogabalin for Treating Taxane-Induced Peripheral Neuropathy in Advanced Lung Cancer.","authors":"Yasuhiro Nakajima, Kozo Kuribayashi, Akio Tada, Akichika Nagano, Toshiyuki Minami, Arihiko Kanehiro, Takashi Kijima","doi":"10.1177/10732748251353327","DOIUrl":"10.1177/10732748251353327","url":null,"abstract":"<p><p>IntroductionTaxane-based cytotoxic anticancer drugs are a cornerstone of advanced lung cancer chemotherapy; however, they often result in chemotherapy-induced peripheral neuropathy (CIPN). Along with prolonged recovery, CIPN may cause irreversible damage. Consequently, dose reduction or discontinuation is justified, potentially impacting therapeutic efficacy. With no established treatment for CIPN, low-dose duloxetine is generally used as a supportive drug. However, studies have shown the potential effect of mirogabalin on CIPN. Therefore, at our hospital, patients with advanced lung cancer experiencing CIPN during taxane-based first-line therapy received low-dose duloxetine, and were subsequently treated with mirogabalin.MethodsIn this study, we conducted a retrospective observational cohort study of the impact of mirogabalin administration on 14 advanced lung cancer patients when duloxetine alone was deemed insufficient. The median age was 71 years (52-89 years), with 9 male and 5 female patients. The Numerical Rating Scale (NRS) was utilized to evaluate outcomes, and Wilcoxon's signed rank-sum test was used in statistical analysis.ResultsThe median Numerical Rating Scale (NRS) score decreased from 5.5 (interquartile range [IQR]: 4.5-7.0) before to 4.0 (IQR: 3.0-5.0) after mirogabalin administration (<i>P</i> = 0.041), indicating significant pain reduction.ConclusionThe addition of mirogabalin to duloxetine shows promise in alleviating CIPN in advanced lung cancer patients treated with taxane anticancer agents. These findings warrant further investigation and consideration for their integration into clinical practice for managing CIPN.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251353327"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}